FOXM1: From cancer initiation to progression and treatment.

The Forkhead box protein M1 (FOXM1) transcription factor is a regulator of myriad biological processes, including cell proliferation, cell cycle progression, cell differentiation, DNA damage repair, tissue homeostasis, angiogenesis and apoptosis. Elevated FOXM1 expression is found in cancers of the liver, prostate, brain, breast, lung, colon, pancreas, skin, cervix, ovary, mouth, blood and nervous system, suggesting it has an integral role in tumorigenesis. Recent research findings also place FOXM1 at the centre of cancer progression and drug sensitivity. In this review the involvement of FOXM1 in various aspects of cancer, in particular its role and regulation within the context of cancer initiation, progression, and cancer drug response, will be summarised and discussed.

[1]  Sathish Kumar Mungamuri,et al.  Foxo3 Is Essential for the Regulation of Ataxia Telangiectasia Mutated and Oxidative Stress-mediated Homeostasis of Hematopoietic Stem Cells* , 2008, Journal of Biological Chemistry.

[2]  I. Vaida,et al.  Tyrosine Kinase Inhibitors and Solid Tumours: Case Report and Review of the Literature , 2009, Pharmacology.

[3]  Peter M Schlag,et al.  Identification of early molecular markers for breast cancer , 2011, Molecular Cancer.

[4]  Lucia Altucci,et al.  A genomic view of estrogen actions in human breast cancer cells by expression profiling of the hormone-responsive transcriptome. , 2004, Journal of molecular endocrinology.

[5]  E. Lam,et al.  FoxM1c Counteracts Oxidative Stress-induced Senescence and Stimulates Bmi-1 Expression* , 2008, Journal of Biological Chemistry.

[6]  N. Hay,et al.  Deregulation of FoxM1b leads to tumour metastasis , 2011, EMBO molecular medicine.

[7]  G. Gusarova,et al.  Ubiquitous Expression of the Forkhead Box M1B Transgene Accelerates Proliferation of Distinct Pulmonary Cell Types following Lung Injury* , 2003, Journal of Biological Chemistry.

[8]  Yan Xu,et al.  Forkhead box M1 transcriptional factor is required for smooth muscle cells during embryonic development of blood vessels and esophagus. , 2009, Developmental biology.

[9]  Vladimir Petrovic,et al.  Forkhead Box M1 Regulates the Transcriptional Network of Genes Essential for Mitotic Progression and Genes Encoding the SCF (Skp2-Cks1) Ubiquitin Ligase , 2005, Molecular and Cellular Biology.

[10]  K. Aldape,et al.  Aberrant FoxM1B expression increases matrix metalloproteinase-2 transcription and enhances the invasion of glioma cells , 2007, Oncogene.

[11]  Z. Jehan,et al.  Genome-wide expression analysis of Middle Eastern colorectal cancer reveals FOXM1 as a novel target for cancer therapy. , 2011, The American journal of pathology.

[12]  N. Davidson,et al.  The forkhead box M1 transcription factor contributes to the development and growth of mouse colorectal cancer. , 2007, Gastroenterology.

[13]  Ricardo H Álvarez,et al.  Present and future evolution of advanced breast cancer therapy , 2010, Breast Cancer Research.

[14]  M. Tretiakova,et al.  The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. , 2006, Cancer research.

[15]  R. Costa,et al.  New and unexpected: forkhead meets ARF. , 2005, Current opinion in genetics & development.

[16]  G. Tortora,et al.  A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  René H Medema,et al.  FoxM1: at the crossroads of ageing and cancer. , 2007, Biochimica et biophysica acta.

[18]  R. Costa,et al.  Premature Expression of the Winged Helix Transcription Factor HFH-11B in Regenerating Mouse Liver Accelerates Hepatocyte Entry into S Phase , 1999, Molecular and Cellular Biology.

[19]  H. Clevers,et al.  The human TRIDENT/HFH-11/FKHL16 gene: structure, localization, and promoter characterization. , 1997, Genomics.

[20]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[21]  P. Fisher,et al.  FOXM1 expression mediates growth suppression during terminal differentiation of HO‐1 human metastatic melanoma cells , 2011, Journal of cellular physiology.

[22]  R. Coombes,et al.  FoxO3a Transcriptional Regulation of Bim Controls Apoptosis in Paclitaxel-treated Breast Cancer Cell Lines* , 2003, Journal of Biological Chemistry.

[23]  K. Scotto,et al.  Amplification and expression of genes associated with multidrug resistance in mammalian cells. , 1986, Science.

[24]  Mario Passalacqua,et al.  Grb7 Upregulation Is a Molecular Adaptation to HER2 Signaling Inhibition Due to Removal of Akt-Mediated Gene Repression , 2010, PloS one.

[25]  S. Teo,et al.  FOXM1 Upregulation Is an Early Event in Human Squamous Cell Carcinoma and it Is Enhanced by Nicotine during Malignant Transformation , 2009, PloS one.

[26]  A. Gartel,et al.  FOXM1: The Achilles' heel of cancer? , 2008, Nature Reviews Cancer.

[27]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[28]  Lara J. Monteiro,et al.  FOXM1 Confers Acquired Cisplatin Resistance in Breast Cancer Cells , 2010, Molecular Cancer Research.

[29]  E. Lam,et al.  The Forkhead Transcription Factor FOXO3a Increases Phosphoinositide-3 Kinase/Akt Activity in Drug-Resistant Leukemic Cells through Induction of PIK3CA Expression , 2008, Molecular and Cellular Biology.

[30]  Lara J. Monteiro,et al.  ATM and p53 Regulate FOXM1 Expression via E2F in Breast Cancer Epirubicin Treatment and Resistance , 2011, Molecular Cancer Therapeutics.

[31]  A. Gartel,et al.  FoxM1 Is a General Target for Proteasome Inhibitors , 2009, PloS one.

[32]  A. Gartel,et al.  Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1. , 2006, Cancer research.

[33]  M. Becich,et al.  Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process , 2007, BMC Cancer.

[34]  A. Cheung,et al.  Raf/MEK/MAPK signaling stimulates the nuclear translocation and transactivating activity of FOXM1c , 2005, Journal of Cell Science.

[35]  K. Yao,et al.  Molecular Analysis of a Novel Winged Helix Protein, WIN , 1997, The Journal of Biological Chemistry.

[36]  Fuminori Tsuruta,et al.  JNK antagonizes Akt-mediated survival signals by phosphorylating 14-3-3 , 2005, The Journal of cell biology.

[37]  J. Whitsett,et al.  Sox2 activates cell proliferation and differentiation in the respiratory epithelium. , 2011, American journal of respiratory cell and molecular biology.

[38]  Julia M. Francis,et al.  FoxO3a and BCR-ABL Regulate cyclin D2 Transcription through a STAT5/BCL6-Dependent Mechanism , 2004, Molecular and Cellular Biology.

[39]  E. Lam,et al.  The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells , 2007, Molecular Cancer Therapeutics.

[40]  E. Lam,et al.  Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells , 2008, Molecular Cancer Therapeutics.

[41]  E. Lam,et al.  The Forkhead Box M1 Protein Regulates the Transcription of the Estrogen Receptor α in Breast Cancer Cells* , 2006, Journal of Biological Chemistry.

[42]  Yongjun Tan,et al.  Foxm1 transcription factor is required for maintenance of pluripotency of P19 embryonal carcinoma cells , 2010, Nucleic acids research.

[43]  W. McGuire,et al.  Steroid hormone receptors in the management of human breast cancer. , 1980, Annals of clinical research.

[44]  E. Lam,et al.  Induction of Mxi1-SRα by FOXO3a Contributes to Repression of Myc-Dependent Gene Expression , 2007, Molecular and Cellular Biology.

[45]  J. Bos,et al.  FOXO transcription factor activation by oxidative stress mediated by the small GTPase Ral and JNK , 2004, The EMBO journal.

[46]  Simak Ali,et al.  Endocrine-responsive breast cancer and strategies for combating resistance , 2002, Nature Reviews Cancer.

[47]  P. Harari,et al.  Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer , 2006, Expert review of anticancer therapy.

[48]  C. Pilarsky,et al.  Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. , 2004, Neoplasia.

[49]  R. Coombes,et al.  Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt. , 2006, Cancer research.

[50]  A. Barsotti,et al.  Pro-proliferative FoxM1 is a target of p53-mediated repression , 2009, Oncogene.

[51]  Jon Clardy,et al.  FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cells , 2008, Molecular Cancer Therapeutics.

[52]  Minoru Watanabe,et al.  FoxM1-driven cell division is required for neuronal differentiation in early Xenopus embryos , 2008, Development.

[53]  E. Lam,et al.  Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression , 2008, Molecular Cancer Therapeutics.

[54]  I. Christensen,et al.  Cell cycle analysis of estrogen stimulation and antiestrogen inhibition of growth of the human breast cancer cell line MCF-7. , 1986, Breast cancer research and treatment.

[55]  M. Follettie,et al.  Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. , 2005, Cancer research.

[56]  G. Natile,et al.  Trans-platinum complexes in cancer therapy. , 2007, Anti-cancer agents in medicinal chemistry.

[57]  F. Holstege,et al.  FOXO3a Induces Differentiation of Bcr-Abl-transformed Cells through Transcriptional Down-regulation of Id1* , 2007, Journal of Biological Chemistry.

[58]  K. Yao,et al.  Over‐expression of FOXM1 transcription factor is associated with cervical cancer progression and pathogenesis , 2008, The Journal of pathology.

[59]  R. Costa,et al.  β-Cell Proliferation, but Not Neogenesis, Following 60% Partial Pancreatectomy Is Impaired in the Absence of FoxM1 , 2008, Diabetes.

[60]  Zhaohui Xu,et al.  Functional interaction between FOXO3a and ATM regulates DNA damage response , 2008, Nature Cell Biology.

[61]  E. Lam,et al.  FOXO and FOXM1 in cancer: the FOXO-FOXM1 axis shapes the outcome of cancer chemotherapy. , 2011, Current drug targets.

[62]  S. Mohammed,et al.  Activation of FoxM1 during G2 Requires Cyclin A/Cdk-Dependent Relief of Autorepression by the FoxM1 N-Terminal Domain , 2008, Molecular and Cellular Biology.

[63]  N. Ready,et al.  Gefitinib therapy for non-small cell lung cancer , 2005, Current treatment options in oncology.

[64]  E. Lam,et al.  Differential expression of FOXO1 and FOXO3a confers resistance to oxidative cell death upon endometrial decidualization. , 2006, Molecular endocrinology.

[65]  E. Lam,et al.  Identification of Cyclin A2 as the Downstream Effector of the Nuclear Phosphatidylinositol 4,5-Bisphosphate Signaling Network* , 2008, Journal of Biological Chemistry.

[66]  E. Lam,et al.  Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells , 2005, Oncogene.

[67]  Christopher M. Overall,et al.  Degradomics: Systems biology of the protease web. Pleiotropic roles of MMPs in cancer , 2006, Cancer and Metastasis Reviews.

[68]  D. Tan,et al.  Critical role and regulation of transcription factor FoxM1 in human gastric cancer angiogenesis and progression. , 2009, Cancer research.

[69]  R. Costa,et al.  Chk2 Mediates Stabilization of the FoxM1 Transcription Factor To Stimulate Expression of DNA Repair Genes , 2006, Molecular and Cellular Biology.

[70]  Hao Li,et al.  Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression , 2008, Nature Cell Biology.

[71]  Valerie Speirs,et al.  ERβ1 represses FOXM1 expression through targeting ERα to control cell proliferation in breast cancer. , 2011, The American journal of pathology.

[72]  Raza Ali,et al.  RETRACTED ARTICLE: FoxM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors , 2010, Breast Cancer Research and Treatment.

[73]  Johan Hartman,et al.  FOXM1 is a transcriptional target of ERα and has a critical role in breast cancer endocrine sensitivity and resistance , 2010, Oncogene.

[74]  L. Coussens,et al.  MMP9 potentiates pulmonary metastasis formation. , 2002, Cancer cell.

[75]  G. Giaccone,et al.  Small-molecule inhibitors of the human epidermal receptor family , 2009, Expert opinion on investigational drugs.

[76]  Raymond Sawaya,et al.  FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. , 2006, Cancer research.

[77]  M. Teh,et al.  Upregulation of FOXM1 induces genomic instability in human epidermal keratinocytes , 2010, Molecular Cancer.

[78]  J. Whitsett,et al.  Forkhead Box m1 transcription factor is required for perinatal lung function , 2008, Proceedings of the National Academy of Sciences.

[79]  Hans Clevers,et al.  FoxM1 is required for execution of the mitotic programme and chromosome stability , 2005, Nature Cell Biology.

[80]  D. Haber,et al.  Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. , 2005, Cold Spring Harbor symposia on quantitative biology.

[81]  M. Tretiakova,et al.  Transgenic expression of the forkhead box M1 transcription factor induces formation of lung tumors , 2008, Oncogene.

[82]  M. Teh,et al.  Induction of human epithelial stem/progenitor expansion by FOXM1. , 2010, Cancer research.

[83]  E. Lam,et al.  FOXO transcription factors: key regulators of cell fate. , 2006, Biochemical Society transactions.

[84]  A. Datta,et al.  Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. , 2004, Genes & development.

[85]  H. Clevers,et al.  Uncoupling of S phase and mitosis in cardiomyocytes and hepatocytes lacking the winged-helix transcription factor Trident , 1998, Current Biology.

[86]  R. Lea,et al.  Integrative genomic profiling reveals conserved genetic mechanisms for tumorigenesis in common entities of non‐Hodgkin's lymphoma , 2011, Genes, Chromosomes and Cancer.

[87]  J. Hartman,et al.  FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer. , 2009, International journal of oncology.

[88]  L. Lim,et al.  Hepatocyte Nuclear Factor 3 / fork head Homolog 11 Is Expressed in Proliferating Epithelial and Mesenchymal Cells of Embryonic and Adult Tissues , 1996 .

[89]  T. Kalin,et al.  Endothelial cell-specific deletion of transcription factor FoxM1 increases urethane-induced lung carcinogenesis. , 2011, Cancer research.

[90]  Vladimir Petrovic,et al.  A cell-penetrating ARF peptide inhibitor of FoxM1 in mouse hepatocellular carcinoma treatment. , 2007, The Journal of clinical investigation.

[91]  N. Brünner,et al.  Endocrine therapy of human breast cancer cells: the role of secreted polypeptide growth factors. , 1989, Cancer cells.

[92]  J. Whitsett,et al.  Increased expression of FoxM1 transcription factor in respiratory epithelium inhibits lung sacculation and causes Clara cell hyperplasia. , 2010, Developmental biology.

[93]  S. Kalinin,et al.  Sustained hepatic expression of FoxM1B in transgenic mice has minimal effects on hepatocellular carcinoma development but increases cell proliferation rates in preneoplastic and early neoplastic lesions , 2003, Oncogene.

[94]  N. Hay,et al.  FoxM1, a critical regulator of oxidative stress during oncogenesis , 2009, The EMBO journal.

[95]  H. Park,et al.  FoxM1 mediates resistance to herceptin and paclitaxel. , 2010, Cancer research.

[96]  Catherine Legrand.  1687Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials : Early Breast Cancer Trialists' Collaborative Group (EBCTCG) , 2005 .

[97]  M. Teh,et al.  FOXM1 is a downstream target of Gli1 in basal cell carcinomas. , 2002, Cancer research.

[98]  T. Tsunoda,et al.  Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. , 2001, Cancer research.

[99]  R. Costa,et al.  Earlier expression of the transcription factor HFH‐11B diminishes induction of p21CIP1/WAF1 levels and accelerates mouse hepatocyte entry into S‐phase following carbon tetrachloride liver injury , 2001, Hepatology.

[100]  Zhiwei Wang,et al.  Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. , 2007, Cancer research.

[101]  A. Carrato,et al.  Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[102]  M. Giraud-Panis,et al.  Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways. , 2005, Current medicinal chemistry. Anti-cancer agents.

[103]  Raymond Sawaya,et al.  FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells. , 2008, Cancer research.

[104]  K. Kaestner,et al.  The mouse Forkhead Box m1 transcription factor is essential for hepatoblast mitosis and development of intrahepatic bile ducts and vessels during liver morphogenesis. , 2004, Developmental biology.

[105]  E. Lam,et al.  Resist or die: FOXO transcription factors determine the cellular response to chemotherapy , 2008, Cell cycle.

[106]  Donegan Wl,et al.  Estrogen receptors and breast cancer: prognostic and therapeutic implications. , 1980, Surgery.

[107]  Robert H. Costa,et al.  Forkhead Box M1B Transcriptional Activity Requires Binding of Cdk-Cyclin Complexes for Phosphorylation-Dependent Recruitment of p300/CBP Coactivators , 2004, Molecular and Cellular Biology.

[108]  M. Björkholm,et al.  FoxM1 is up‐regulated in gastric cancer and its inhibition leads to cellular senescence, partially dependent on p27kip1 , 2009, The Journal of pathology.

[109]  E. Lam,et al.  The emerging roles of forkhead box (Fox) proteins in cancer , 2007, Nature Reviews Cancer.

[110]  E. Lam,et al.  Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer , 2009, Molecular Cancer Therapeutics.

[111]  E. Lam,et al.  FOXO transcription factors: from cell fate decisions to regulation of human female reproduction. , 2009, Advances in experimental medicine and biology.

[112]  D. Miles,et al.  Rechallenging with anthracyclines and taxanes in metastatic breast cancer , 2010, Nature Reviews Clinical Oncology.

[113]  H. Guchelaar,et al.  Clinical pharmacokinetics of tyrosine kinase inhibitors. , 2009, Cancer treatment reviews.

[114]  Satoki Nakamura,et al.  The FOXM1 transcriptional factor promotes the proliferation of leukemia cells through modulation of cell cycle progression in acute myeloid leukemia. , 2010, Carcinogenesis.

[115]  R. Costa,et al.  Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice. , 2006, Cancer research.